Evaluation of Long-Term Safety and Tolerability of ETC-1002 in High-Risk Patients With Hyperlipidemia and High CV Risk (CLEAR Harmony)
Part of paid clinical trials in Huntsville, Alabama.
- Sponsor
- Esperion Therapeutics, Inc.
- Study ID
- NCT02666664
- Phase
- PHASE3
- Status
- Completed
Conditions
- Atherosclerotic Cardiovascular Diseases
- Hypercholesterolemia
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- ETC-1002 — DRUGETC-1002 180 mg tablets taken orally, once per day. Patients remain on ongoing statin therapy (not study provided)
- Placebo — DRUGMatching placebo tablets taken orally, once per day. Patients remain on ongoing statin therapy (not study provided)
Study Details
The purpose of this study is to see if ETC-1002 (bempedoic acid) is safe and well-tolerated versus placebo in patients with high cardiovascular risk and elevated LDL cholesterol that is not adequately controlled by their current therapy.
Key Dates
- Start date
- Jan 21, 2016
- Status verified
- Apr 2020
- Primary completion
- Feb 21, 2018
- Completion
- Mar 28, 2018
Study Design
- Enrollment
- 2,230 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: ETC-1002ETC-1002 180 mg/day
- Placebo Comparator: PlaceboPlacebo control
Primary Outcome Measure
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) [ Time Frame: Up to approximately 52 weeks ]
Locations (48)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| - | Huntsville | Alabama | - | - |
| - | Cottonwood | Arizona | - | - |
| - | Phoenix | Arizona | - | - |
| - | Canoga Park | California | - | - |
| - | Santa Rosa | California | - | - |
| - | Bridgeport | Connecticut | - | - |
| - | Hartford | Connecticut | - | - |
| - | Atlantis | Florida | - | - |
| - | Boca Raton | Florida | - | - |
| - | Crestview | Florida | - | - |
| - | Crystal River | Florida | - | - |
| - | Daytona Beach | Florida | - | - |
| - | Lake Worth | Florida | - | - |
| - | Miami Lakes | Florida | - | - |
| - | Tampa | Florida | - | - |
| - | Park Ridge | Illinois | - | - |
| - | Iowa City | Iowa | - | - |
| - | Overland Park | Kansas | - | - |
| - | Covington | Kentucky | - | - |
| - | Louisville | Kentucky | - | - |
| - | Minden | Louisiana | - | - |
| - | Monroe | Louisiana | - | - |
| - | Shreveport | Louisiana | - | - |
| - | Auburn | Maine | - | - |
| - | Midland | Michigan | - | - |
| - | Saginaw | Michigan | - | - |
| - | Saint Cloud | Minnesota | - | - |
| - | Tupelo | Mississippi | - | - |
| - | Jefferson City | Missouri | - | - |
| - | Nashua | New Hampshire | - | - |
| - | Bridgewater | New Jersey | - | - |
| - | Cary | North Carolina | - | - |
| - | Mount Airy | North Carolina | - | - |
| - | Raleigh | North Carolina | - | - |
| - | Rocky Mount | North Carolina | - | - |
| - | Wilmington | North Carolina | - | - |
| - | Cincinnati | Ohio | - | - |
| - | Sandusky | Ohio | - | - |
| - | Willoughby | Ohio | - | - |
| - | Hillsboro | Oregon | - | - |
| - | Fort Worth | Texas | - | - |
| - | Houston | Texas | - | - |
| - | Katy | Texas | - | - |
| - | Kingwood | Texas | - | - |
| - | Orem | Utah | - | - |
| - | Richmond | Virginia | - | - |
| - | Puyallup | Washington | - | - |
| - | Tacoma | Washington | - | - |
Related Studies
- Alirocumab in Patients on a Stable Dialysis RegimenPHASE3 · Recruiting · Baylor Research Institute · Dallas, Texas
- Emergency Medicine Cardiovascular Risk Assessment for Lipid Disorders TrialPHASE2 · Recruiting · Wake Forest University Health Sciences · Winston-Salem, North Carolina
- Pharmacogenomic Informed Statin PrescribingRecruiting · VA Office of Research and Development · Indianapolis, Indiana
- Vascular Intervention Strategies Trial for Alzheimer'sPHASE2 · Not Yet Recruiting · University of Southern California · Los Angeles, California